Vein of Marshall Ethanol Infusion for Recurrent Atrial Fibrillation Patients Presenting for Redo Ablation: A Systematic Review and Meta‐Analysis
Journal of Cardiovascular Electrophysiology · 2026-06 · 37 (6) · 1340-1352
DOI: 10.1111/jce.70363 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 15.05.2026. Verfasst von Joey Junarta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Leon H. Charney Division of Cardiology, NYU Langone Health, New York, New York, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Ethanol, Catheter Ablation. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Randomized trials of ethanol infusion into the vein of Marshall (EIVOM) have shown efficacy in preventing atrial fibrillation (AF) recurrence in patients presenting for de novo ablation. The utility of EIVOM in AF patients who present for redo ablation is unclear. This meta‐analysis was reported according to the Preferred Reporting Items for Systematic Review and Meta‐Analyses guidelines. Medline, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched to identify relevant studies. Risk of bias was assessed using the Modified Newcastle‐Ottawa scale. Eligible studies reported outcomes in AF patients with previous ablation who underwent redo catheter ablation (CA) alone vs. combined redo CA and EIVOM. Five observational studies comprising 568 patients were included. When comparing combined redo CA and EIVOM vs. redo CA alone, pooled results showed no difference in freedom from arrhythmia (FFA) in all patients (risk ratio [RR] 1.13; 95% confidence interval [CI] 0.96–1.33), FFA in persistent AF patients only (RR 1.08; 95% CI 0.90–1.29), total procedure time (mean difference −0.59; 95% CI −41.04–39.85), or major periprocedural complications (RR 0.81; 95% CI 0.06–11.64). Patients with AF recurrence after ablation represent a difficult‐to‐treat population. Salvage therapy with combined CA and EIVOM did not improve arrhythmic outcomes compared to CA alone in AF patients who presented for redo ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leon H. Charney Division of Cardiology, NYU Langone Health, New York, New York, USA.
- Department of Medicine, MetroHealth Medical Center Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Internal Medicine, NYU Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Angela Wang, Brian Hsia, Larry A Chinitz
Zitieren
APA
Junarta, J., Simadibrata, D. M., Wang, A., Hsia, B., Garber, L., Barbhaiya, C. R., Jankelson, L., Park, D. S., Holmes, D., Kushnir, A., Chinitz, L. A., & Aizer, A. (2026). Vein of Marshall Ethanol Infusion for Recurrent Atrial Fibrillation Patients Presenting for Redo Ablation: A Systematic Review and Meta‐Analysis. Journal of Cardiovascular Electrophysiology, 37(6), 1340-1352. https://doi.org/10.1111/jce.70363
Vancouver
Junarta J, Simadibrata DM, Wang A, Hsia B, Garber L, Barbhaiya CR, et al. Vein of Marshall Ethanol Infusion for Recurrent Atrial Fibrillation Patients Presenting for Redo Ablation: A Systematic Review and Meta‐Analysis. Journal of Cardiovascular Electrophysiology. 2026;37(6):1340-1352. doi:10.1111/jce.70363
BibTeX
@article{Junarta2026,
author = {Junarta, Joey and Simadibrata, Daniel M and Wang, Angela and Hsia, Brian and Garber, Leonid and Barbhaiya, Chirag R and Jankelson, Lior and Park, David S and Holmes, Douglas and Kushnir, Alexander and Chinitz, Larry A and Aizer, Anthony},
title = {Vein of Marshall Ethanol Infusion for Recurrent Atrial Fibrillation Patients Presenting for Redo Ablation: A Systematic Review and Meta‐Analysis},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2026},
volume = {37},
number = {6},
pages = {1340--1352},
doi = {10.1111/jce.70363}
}
EUVIMED